Results per Page:
HIV prevention: does 1+1 = 2?
From HIV Vaccine Trials Network and the HIV Prevention Trials Network, Vaccine and Infectious Disease Division
Exploring the impact of prophylactic treatment on HIV prevention in marginalized communities
From the Meisner research group, Public Health Sciences Division
Using mathematical models to tell time of initial HIV infection in infants
From the Overbaugh/Lehman Lab, Cancer Consortium and Human Biology Division
Rethinking the When and Where of HIV PrEP service delivery
From the Ortblad Lab, Public Health Sciences Division
Expanding the delivery of HIV pre-exposure prophylaxis (PrEP) in Kenya
From the Ortblad Lab, Public Health Sciences Division
Injectable HIV drug prevents infections
Early data shows fewer infections than with daily pill; trial halted
New HIV vaccine trial to launch in U.S., Latin America and Europe
‘Mosaico’ will enroll 3,800 transgender people and men who have sex with men
HIV prevention gains bring hope — and challenges
Injectable PrEP and other options are in the pipeline, and that makes clinical trials more complicated
Charlie Sheen’s announcement reveals ‘ugly ogre underneath’ public awareness of HIV
Reactions underscore disease’s lingering stigma